N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy
- 270 Downloads
Among patients hospitalized with acute heart failure (HF), the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in short-term stroke prediction remains unclear.
In the APEX trial, 7513 patients hospitalized for an acute medical illness were randomized to receive either extended-duration betrixaban (80 mg once daily for 35–42 days) or standard-of-care enoxaparin (40 mg once daily for 10 ± 4 days) for venous thromboprophylaxis. Baseline NT-proBNP concentrations were obtained in 3261 patients admitted for HF. Stroke events were adjudicated by an independent clinical events committee blinded to thromboprophylaxis allocation. The association of NT-proBNP level and other risk factors and biomarkers with stroke was assessed at 77 days after randomization.
In univariate analysis, the risk of stroke at 77 days was associated with baseline NT-proBNP (HR 3.63 [95% CI 1.47–8.99]; P = 0.005), D-dimer (HR 2.73 [95% CI 1.03–7.20]; P = 0.043), and hsCRP (HR 3.03 [95% CI 1.36–6.75]; P = 0.007). In multivariable analysis adjusting for hsCRP and thromboprophylaxis, NT-proBNP was associated with the risk of stroke (adjusted HR 3.64 [95% CI 1.35–9.83]; P = 0.011). The interaction of NT-proBNP with the treatment effect was not significant (Pint = 0.30).
Baseline NT-proBNP concentration was associated with short-term stroke among patients hospitalized with acute HF. Stroke risk assessment models should consider incorporation of NT-proBNP measurement.
KeywordsNatriuretic peptide NT-proBNP Stroke Heart failure Thromboprophylaxis
Acute Medically Ill VTE Prevention with Extended Duration Betrixaban trial
Brain natriuretic peptide
High-sensitivity C-reactive protein
N-terminal pro-B-type natriuretic peptide
Transient ischemic attack
Upper limit of normal
The study was funded by the Portola Pharmaceuticals Inc.
Compliance with ethical standards
Conflict of interest
Dr. Chi has received research grant support paid to the Beth Israel Deaconess Medical Center from Portola, Bayer, and Janssen Research. Dr. Januzzi is supported by the Hutter Family Professorship; has received grant support from Siemens, Singulex, and Prevencio; has received consulting income from Roche Diagnostics, Critical Diagnostics, Sphingotec, Phillips, Novartis, Janssen and Boehringer Ingelheim; and participates in clinical endpoint committees/data safety monitoring boards for Pfizer, Novartis, Amgen, Janssen, and Boehringer Ingelheim. Dr. Korjian has received research grant support paid to the Beth Israel Deaconess Medical Center from Portola, Bayer, and Janssen Research. Dr. Daaboul has received research grant support paid to the Beth Israel Deaconess Medical Center from Portola, Bayer, and Janssen Research. Dr. Goldhaber has provided consulting for Boehringer Ingelheim, Bayer, Portola, Daiichi-Sankyo, Janssen, BiO2 Medical, EKOS/BTG, BMS, and Zafgen. Dr. Hernandez reports receipt of grant support from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Luitpold, Merck, and Novartis; and personal fees from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Scientific, Luitpold, and Novartis outside the submitted work. Dr. Hull reports grant support from Portola Pharmaceuticals during the conduct of the study, and grant support and personal fees from Leo Pharma outside the submitted work. Dr. Gold reports personal fees (salary support) from Portola Pharmaceuticals outside the submitted work. Dr. Cohen reports grant support, personal fees, and non-financial support from Portola Pharmaceuticals during the conduct of the study; grant support, personal fees, and non-financial support from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Janssen, and Bayer Pharmaceuticals, personal fees from Boehringer Ingelheim and Sanofi, and personal fees and non-financial support from Johnson & Johnson and Aspen Pharmaceuticals outside the submitted work. Dr. Harrington reports grant support from Portola Pharma during the conduct of the study; grant support from CSL Behring, AstraZeneca, GlaxoSmithKline, Regado, and Sanofi Aventis, grant support and personal fees from Merck and The Medicines Company, personal fees from Amgen, Gilead Sciences, MyoKardia, and WebMD, and other support from Scanadu, SignalPath, Element Science, Vida Health, and Adverse Events outside the submitted work. Dr. Gibson reports research grant support from Portola Pharmaceuticals during the conduct of the study, and grant support from Johnson & Johnson and Bayer outside the submitted work all of which was paid to the Beth Israel Deaconess Medical Center. He has also received modest consulting fees from these same entities in compliance with hospital and Harvard Medical School policies.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, Mensah GA, Norrving B, Shiue I, Ng M, Estep K, Cercy K, Murray CJ, Forouzanfar MH, Global Burden of Diseases I, Risk Factors S, Stroke Experts Writing G (2016) Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 15:913–924. doi: 10.1016/S1474-4422(16)30073-4 CrossRefPubMedGoogle Scholar
- 2.ClinicalTrials.gov. Venous thromboembolic Event (VTE) Prophylaxis in medically Ill patients (MAGELLAN). https://clinicaltrials.gov/ct2/show/NCT00571649
- 3.Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT, Investigators A (2016) Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically Ill patients: an APEX trial substudy (acute medically ill venous thromboembolism prevention with extended duration betrixaban). Circulation. doi: 10.1161/CIRCULATIONAHA.116.025427 Google Scholar
- 8.Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616. doi: 10.1001/jama.293.13.1609 CrossRefPubMedGoogle Scholar
- 9.Cushman M, Judd SE, Howard VJ, Kissela B, Gutierrez OM, Jenny NS, Ahmed A, Thacker EL, Zakai NA (2014) N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke 45:1646–1650. doi: 10.1161/STROKEAHA.114.004712 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125:1605–1616. doi: 10.1161/CIRCULATIONAHA.111.038729 CrossRefPubMedGoogle Scholar
- 11.Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB (2013) N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol 61:2274–2284. doi: 10.1016/j.jacc.2012.11.082 CrossRefPubMedGoogle Scholar
- 13.Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Kitt MM, Lorenz TJ (2014) The design and rationale for the acute medically Ill venous thromboembolism prevention with extended duration Betrixaban (APEX) Study. Am Heart J 167:335–341. doi: 10.1016/j.ahj.2013.11.006 CrossRefPubMedGoogle Scholar
- 14.Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL (2015) 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 66:403–469. doi: 10.1016/j.jacc.2014.12.018 CrossRefPubMedGoogle Scholar
- 15.Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27:330–337. doi: 10.1093/eurheartj/ehi631 CrossRefPubMedGoogle Scholar
- 17.Llombart V, Antolin-Fontes A, Bustamante A, Giralt D, Rost NS, Furie K, Shibazaki K, Biteker M, Castillo J, Rodriguez-Yanez M, Fonseca AC, Watanabe T, Purroy F, Zhixin W, Etgen T, Hosomi N, Jafarian Kerman SR, Sharma JC, Knauer C, Santamarina E, Giannakoulas G, Garcia-Berrocoso T, Montaner J (2015) B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. Stroke 46:1187–1195. doi: 10.1161/STROKEAHA.114.008311 CrossRefPubMedGoogle Scholar
- 18.Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB (2005) The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954. doi: 10.1016/j.amjcard.2004.12.032 CrossRefPubMedGoogle Scholar
- 20.Januzzi JL Jr, Sakhuja R, O’Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA Jr, Lloyd-Jones DM (2006) Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 166:315–320. doi: 10.1001/archinte.166.3.315 CrossRefPubMedGoogle Scholar
- 21.Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD (2016) Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 68:2425–2436. doi: 10.1016/j.jacc.2016.09.931 CrossRefPubMedGoogle Scholar
- 22.Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E, Investigators P (2007) Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 50:205–214. doi: 10.1016/j.jacc.2007.03.038 CrossRefPubMedGoogle Scholar
- 23.Mishra RK, Beatty AL, Jaganath R, Regan M, Wu AH, Whooley MA (2014) B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the heart and soul study. J Am Heart Assoc 3:e000907. doi: 10.1161/JAHA.114.000907 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L, Re LY, Investigators A (2016) Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation 134:1697–1707. doi: 10.1161/CIRCULATIONAHA.116.022802 CrossRefPubMedGoogle Scholar
- 25.Ruff CT, Giugliano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, Mercuri M, Antman EM, Morrow DA (2016) Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: a subanalysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol 1:999–1006. doi: 10.1001/jamacardio.2016.3311 CrossRefPubMedGoogle Scholar